MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

Du Xiangnan; Lin Benjamin C.; Wang Qian-Rena; Li Hao; Ingalla Ellen; Tien Janet; Rooney Isabelle; Ashkenazi Avi; Penuel Elicia; Qing Jing

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

【24h】

MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

机译：MMP-1和Pro-MMP-10作为膀胱癌患者FGFR3靶向治疗的潜在尿液药理生物标志物

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: The aim of this study was to identify noninvasive pharmacodynamic biomarkers of FGFR3-targeted therapies in bladder cancer to facilitate the clinical development of experimental agent targeting FGFR3.

机译：目的：本研究的目的是鉴定针对FGFR3靶向疗法在膀胱癌中的非侵入性药效生物标志物，以促进针对FGFR3的实验药物的临床开发。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2014年第24期|共12页
作者
Du Xiangnan; Lin Benjamin C.; Wang Qian-Rena; Li Hao; Ingalla Ellen; Tien Janet; Rooney Isabelle; Ashkenazi Avi; Penuel Elicia; Qing Jing;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer [J] . Du Xiangnan, Lin Benjamin C., Wang Qian-Rena, Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第24期

机译：MMP-1和Pro-MMP-10作为膀胱癌患者FGFR3靶向治疗的潜在尿液药理生物标志物
2. Regular article Biomarkers, genomics, proteomics, and gene regulation Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder [J] . Stefan Garczyk, Nadina Ortiz-Brüchle, Ursula Schneider, The American journal of pathology. . 2020,第2期

机译：常规文章生物标志物，基因组学，蛋白质组学和基因调节下一代测序揭示了潜在的预测生物标志物和尿液癌的尿路上皮癌治疗靶标
3. Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential [J] . R T Bryan, N J Shimwell, W Wei, British Journal of Cancer . 2014,第3期

机译：尿路上皮膀胱癌患者的尿液EpCAM：表征和生物标志物潜力评估
4. Discovery of urinary glycoprotein biomarkers in bladder cancer [C] . Na Yang, Shun Feng, Kerby Shedden, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：膀胱癌中尿糖蛋白生物标志物的发现
5. Cystoscopy and the development of invasive bladder cancer in patients presenting with superficial urinary bladder cancer. [D] . Amos, Charles E., Jr. 2003

机译：膀胱镜检查和浅表性膀胱癌患者的浸润性膀胱癌的发展。
6. A phase II randomized double-blind presurgical trial of Polyphenon E in bladder cancer patients to evaluate pharmacodynamics and bladder tissue biomarkers [O] . Jason R. Gee, Daniel R. Saltzstein, KyungMann Kim, -1

机译：Polyphenon E在膀胱癌患者中进行的II期随机双盲术前试验以评估药效学和膀胱组织生物标志物
7. Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. [O] . Bryan, R.T., Shimwell, N. J., Wei, W., 2014

机译：尿路上皮膀胱癌患者的尿液EpCAM：生物标志物潜力的表征和评估。

MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer

摘要

著录项

相似文献

相关主题

期刊订阅